摘要
目的 观察依折麦布和瑞舒伐他汀联合应用,强效降脂治疗对冠状动脉临界病变患者冠状动脉斑块以及炎症因子的影响,并分析可能的相关机制.方法 选取冠状动脉临界病变合并高脂血症患者47例,随机分为两组,依折麦布＋瑞舒伐他汀组22例,给予依折麦布10 mg,每日睡前服用＋瑞舒伐他汀10 mg,每日睡前服用；瑞舒伐他汀组25例,给予瑞舒伐他汀10 mg,每日睡前服用.分别于治疗前及治疗后6个月检测血脂水平和高敏C-反应蛋白（hs-CRP）水平,以血管内超声（IVUS）和虚拟组织成像技术（VH-IVUS）检测治疗前后冠状动脉内斑块面积和成分变化.结果 治疗6个月后,依折麦布＋瑞舒伐他汀组能进一步降低血总胆固醇、低密度脂蛋白胆固醇及hs-CRP水平,与瑞舒伐他汀组比较差异有统计学意义.同时依折麦布＋瑞舒伐他汀组较瑞舒伐他汀组能显著降低斑块负荷、斑块截面积、薄纤维帽斑块的比率以及斑块中坏死成分百分比（P＜0.05）.结论 依折麦布＋瑞舒伐他汀组可明显降低血脂水平和斑块负荷,改善斑块的稳定性,这可能与其能强效抑制炎症因子表达有关.
Objective To observe the effect of ezetimibe combined with rosuvastatin on coronary plaques and high sensitivity C-reactive protein（hs-CRP） level in patients with coronary boderline lesions, and analyze the possible machanism. Methods A total of 47 patients with coronary boderline lesions were randomly divided into two groups, 22 patients in ezetimibe combined with rosuvastatin treatment group were given ezetimibe 10 rag, quaque nocte and rosuvastatin 10 mg, quaque nocte; Twenty-five patients in rosuvastatin treatment ~rnun w,~,~,~ ,,;,,,~ ~.~,.-_ 1 r^and hs-CRP levels were detected before treatment and 6 months after treatment. Coronary plaques area and plaques composi-tion were detected by intravascular unhrasound and VH-IVUS at the same time. Results At 6 months after treatment, compared with rosuvastatint treatment group, ezetimibe and rosuvastatin combined treatment could significantly reduce the serum lipid and hs-CRP levels, there were significant differences. At the same time, ezetimibe and rosuvastatin combined treatment significantly decreased coronary plaques area, plaques burden, thin fibrous cap plaques ratio and percentage of necrosis element in plaques. Conclusions Ezetimibe and rosuvastatin combined treatment can significantly decrease se- rum lipid level, coronary plaques area and plaques burden of coronary boderline lesions, which may be associated with reduced hs-CRP level.
出处
《中国实用医刊》
2013年第18期38-41,共4页
Chinese Journal of Practical Medicine
